UnitedHealth Moving, Slowly, Toward More Value-Based Drug Contracts
This article was originally published in The Pink Sheet Daily
Executive Summary
Insurer plans to execute more value-based contracts in next two years, but they will be pilot projects layered on top of existing rebate contracts.
You may also be interested in...
The Outcomes-Based Reimbursement Experiment
US payers and drug companies are showing interest in outcomes-based contracts and even implementing some but whether they will become the reimbursement arrangements of the future remains highly uncertain.
UnitedHealth Cancer Care Pilot Reduced Overall Costs Despite Higher Drug Spending
The bundled payment pilot program resulted in a 34% decrease in overall cancer treatment costs among participating medical centers despite a 179% increase in drug spending, according to results released July 8.
Merck’s Winrevair Well Positioned To Benefit From Medicare Part D Redesign
Significant cost sharing reductions under the redesign will enhance uptake of the pulmonary arterial hypertension drug. The trade-off is a 20% mandatory price discount in the catastrophic phase.